The FDA cleared Prelude Therapeutics this week to open a Phase 1 trial for PRT13722, its oral KAT6A degrader in HR-positive breast cancer, a signal that the program has cleared its first regulatory gate and can now enroll patients. The IND clearance is the narrowest possible green light, not efficacy data, but it puts PRT13722 into a space where the treatment options are actively shifting: AstraZeneca’s camizestrant (Etcamah) received accelerated FDA approval just three days earlier, on September 7, for HR-positive, HER2-negative metastatic breast cancer with ESR1 mutations in patients already on aromatase inhibitor and CDK4/6 inhibitor therapy.
PRT13722 works by recruiting the ubiquitin-proteasome system to degrade KAT6A, a histone acetyltransferase that regulates gene transcription in hormone-driven tumor cells. Published preclinical work on KAT6A degraders has shown potent target engagement at sub-nanomolar concentrations, which gives the class a mechanistic rationale, though whether that translates to clinical activity in patients is exactly what the Phase 1 is designed to test. Prelude’s bet is that targeting a transcriptional regulator rather than the estrogen receptor directly offers a different angle on the tumor’s hormone-driven machinery.
Prelude has run this playbook before with PRT3789, its SMARCA2 degrader, where the company moved from IND clearance through proof-of-concept data showing anti-tumor activity in SMARCA4-deficient solid tumors. The SMARCA2 program established that Prelude can take a protein degrader through early clinical work, which gives PRT13722 some organizational precedent to lean on. The company built its identity around targeted protein degradation, and PRT13722 is its attempt to extend that approach into a far larger patient population than the SMARCA4-deficient niche.
What to watch now is dose escalation pace and any early pharmacodynamic readouts confirming that PRT13722 actually degrades KAT6A in patient tumor tissue. A degrader that hits its target in a cell line but fails to achieve sufficient exposure in vivo is where many programs in this class have stalled. The Phase 1 design, including the biomarker sampling strategy, will say a lot about how Prelude plans to answer that question.
Source link: https://www.sec.gov/Archives/edgar/data/1678660/000119312526387232/prld-20260910.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
